WELLVONE Oral suspension Ref.[6327] Active ingredients: Atovaquone

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2023  Publisher: Glaxo Wellcome UK Ltd, trading as GlaxoSmithKline UK, GSK Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK

Therapeutic indications

Wellvone Suspension is indicated for:

Acute treatment of mild to moderate Pneumocystis pneumonia (PCP, caused by Pneumocystis jiroveci, formerly classified as P. carinii) (alveolar – arterial oxygen tension difference [(A-a) DO2] ≤45 mmHg (6 kPa) and oxygen tension in arterial blood (PaO2) ≥60 mmHg (8 kPa) breathing room air) in patients who are intolerant of co-trimoxazole therapy (see section 4.4).

Posology and method of administration

The importance of taking the full prescribed dose of Wellvone with food should be stressed to patients. The presence of food, particularly high fat food, increases bioavailability two to three fold.

The 5 ml end (larger end) of the measuring spoon included in the pack must be used to measure the required dose.

Dosage in adults

Pneumocystis pneumonia

The recommended oral dose is 750 mg twice a day (1 × 5 ml morning and evening) administered with food each day for 21 days.

Higher doses may be more effective in some patients (see section 5.2).

Dosage in Children

Clinical efficacy has not been studied.

Dosage in Older people

There have been no studies of Wellvone in the elderly (see section 4.4).

Renal or hepatic impairment

Wellvone has not been specifically studied in patients with significant hepatic or renal impairment (see section 5.2 for pharmacokinetics in adults). If it is necessary to treat such patients with Wellvone, caution is advised and administration should be closely monitored. Wellvone contains benzyl alcohol (see section 4.4).


There is insufficient experience to predict the consequences or suggest specific management of atovaquone overdose. However, in the reported cases of overdosage, the observed effects were consistent with known undesirable effects of the drug. If overdosage occurs, the patient should be monitored and standard supportive treatment applied.

Shelf life

12 months.

After first opening, the suspension may be stored for up to 21 days.

Special precautions for storage

Do not store above 25°C.

Do not freeze.

Nature and contents of container

A 240 ml high density polyethylene bottle with child resistant polypropylene closure, containing 226 ml of atovaquone suspension.

A double ended measuring spoon (polypropylene) is included, however, only 5 ml end (larger end) of the measuring spoon must be used.

Special precautions for disposal and other handling

Do not dilute.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.